# Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

> **NCT04582084** · — · COMPLETED · sponsor: **AryoGen Pharmed Co.** · enrollment: 583 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT04582084
- **Lead sponsor:** AryoGen Pharmed Co.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-04
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-03-19
- **Target enrollment:** 583 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582084, "Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04582084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*